Reshma Jagsi, MD, DPhil, department chair for radiation oncology at Emory University School of Medicine, and Richard Zellers, MD, department chair for radiation oncology at Indiana University School of Medicine, discuss endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients with genomically-selected favorable Stage I breast cancer.

Debra Pratt, MD, PhD, MBA, FASCO, executive vice president of Texas Oncology and clinical professor at the Dell Medical School at the University of Texas at Austin, discusses controversies in local regional care with Symposium Program Director Kate Lathrop, MD.

Komal Jhaveri, MD, clinical director for early drug development service at Memorial Sloan Kettering Cancer Center, and Julie Nangia, MD, medical director of breast oncology at Baylor College of Medicine, discuss a randomized phase 3 study of datopotamab deruxtecan vs chemotherapy — how does this trial change our treatment algorithm?

Terry Mamounas, MD, medical director of the Comprehensive Breast Program at Orlando Health Cancer Institute, speaks with Hope Rugo, MD, about radiation management of the axilla after response to neoadjuvant therapy – can we de-escalate?

Carol Fabian, MD, director of breast cancer prevention and survivorship at the University of Kansas Medical Center, and Seema Khan, MD, professor of breast surgical oncology at Northwestern Medicine, discuss breast cancer prevention.

Sara Hurvitz, MD, FACP, Senior Vice President and director of the Clinical Research Division at Fred Hutchinson Cancer Center, speaks to SABCS Program Director Kate Lathrop, MD, about the primary analysis of HER2CLIMB-02: Tucatinib and Trastuzumab Emtansine for HER2-Positive Metastatic Breast Cancer.

Jason Mouabbi, MD, assistant professor and medical oncologist at MD Anderson Cancer Center, speaks with SABCS Program Director Kate Lathrop, MD, about the challenges of treating lobular breast cancer and impactful scientific advancements to be presented at SABCS.

Sarah Sammons, MD, associate director of the metastatic breast cancer program at Dana-Farber Cancer Institute, and Virginia Kaklamani, MD, leader of the breast medical oncology program at Mays Cancer Center at UT Health San Antonio, reflect on the highest impact science of 2023 in breast cancer research.

Hope Rugo, MD, FASCO, director of breast oncology at the University of California San Francisco, and Kate Lathrop, MD, breast medical oncologist at Mays Cancer Center at UT Health San Antonio, give their opinions on the sessions and presentations they are most excited to see.